Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium/Salmeterol FDC vs Single Agents in COPD
NCT00662740Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of tiotropium and salmeterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change From Baseline in Trough Forced Expiratory Volume in One Second at 24 weeks, Forced Expiratory Volume in One Second Area Under the Concentration-time Curve From 0 to 8h and 4 more. Started Apr 2008; status: terminated.
02
Drugs
tiotropiumsalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00662740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662740.